Iovance Biotherapeutics(IOVA) The Motley Fool·2024-12-19 09:02Group 1: Investment Opportunities - The article highlights three stocks that are considered attractive investment opportunities before the end of 2024, particularly as they are currently priced at a discount from their highs [2][3]. Group 2: The Coca-Cola Company - The Coca-Cola Company has experienced a 1% decline in drink sales compared to the same quarter last year, leading to a 14% drop in stock price from its peak in September [3][4]. - Despite recent challenges, Coca-Cola is viewed as a steady grower with a reliable earnings engine, having raised its annual dividend for 62 consecutive years [5][6]. - The company's market dominance and brand recognition contribute to its long-term success, making the recent stock decline an attractive buying opportunity [6]. Group 3: Uber Technologies - Uber Technologies reported 161 million rides last quarter, generating $11.2 billion in revenue, marking a year-over-year increase of 13% and 22% respectively [7][8]. - Analysts project Uber's revenue to grow by 17% this year and nearly 16% next year, with the global ride-hailing market expected to grow over 11% annually through 2032 [9][10]. - The company is now consistently profitable, with earnings per share expected to rise from $0.87 last year to $1.89 this year, and further to $2.31 next year [10][11]. Group 4: Iovance Biotherapeutics - Iovance Biotherapeutics is a biopharma company with its flagship drug, Amtagvi, recently receiving FDA approval, although its stock has declined over 50% since the approval [12][14]. - Expected revenue for Iovance is projected to be between $160 million and $165 million for the current fiscal year, with growth anticipated to reach $450 million to $475 million next year [15]. - The company is on track to potentially achieve profitability by 2027, with ongoing trials for Amtagvi indicating a possibility of exceeding $1 billion in annual revenue by 2030 [16].